Repositioning Immunotherapy in VetArans With Lung Cancer - Trial NCT06275360
Access comprehensive clinical trial information for NCT06275360 through Pure Global AI's free database. This Phase 2 trial is sponsored by VA Office of Research and Development and is currently Recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
VA Office of Research and Development
Timeline & Enrollment
Phase 2
Mar 01, 2024
Mar 31, 2030
Primary Outcome
Progression-free survival,Treatment Tolerance
Summary
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of
 chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage
 III NSCLC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06275360
Non-Device Trial